Thr54
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr54  -  EEF2 (human)

Site Information
AsArAGEtRFtDtRk   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 466363

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 )
Disease tissue studied:
breast cancer ( 3 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 , 3 ) , leukemia ( 7 , 14 ) , acute myelogenous leukemia ( 7 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 6 ) , acute megakaryoblastic leukemia (M7) ( 6 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 6 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 6 ) , acute myeloblastic leukemia, without maturation (M1) ( 6 ) , chronic myelogenous leukemia ( 14 ) , B cell lymphoma ( 6 ) , non-Hodgkin's lymphoma ( 6 ) , ovarian cancer ( 3 ) , multiple myeloma ( 6 )
Relevant cell line - cell type - tissue:
A549 (pulmonary) ( 4 ) , AML-193 (monocyte) ( 6 ) , breast ( 1 , 3 ) , CMK (megakaryoblast) ( 6 ) , CTS (myeloid) ( 6 ) , DOHH2 ('B lymphocyte, precursor') ( 6 ) , HEL (erythroid) ( 6 ) , HeLa (cervical) ( 2 , 13 ) , HUES-9 ('stem, embryonic') ( 12 ) , Jurkat (T lymphocyte) ( 8 , 9 , 10 , 11 ) , K562 (erythroid) ( 14 ) , Kasumi-1 (myeloid) ( 6 ) , KG-1 (myeloid) ( 6 ) , MV4-11 (macrophage) ( 6 , 7 ) , OPM-2 (plasma cell) ( 6 ) , ovary ( 3 ) , P31/FUJ (erythroid) ( 6 , 7 ) , RL ('B lymphocyte, precursor') ( 6 ) , RPMI-8226 (plasma cell) ( 6 ) , SU-DHL-6 (B lymphocyte) ( 6 ) , U266 (plasma cell) ( 6 )

Upstream Regulation
Treatments:
PI-103 ( 7 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

4

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

5

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

6

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

7

Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66
22547687   Curated Info

8

Mulhern D (2011) CST Curation Set: 13072; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

9

Mulhern D (2011) CST Curation Set: 12398; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

10

Guo A (2011) CST Curation Set: 12059; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

11

Guo A (2011) CST Curation Set: 12060; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

12

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

13

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

14

Possemato A (2007) CST Curation Set: 2720; Year: 2007; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKA Substrate Antibody Cat#: 9621
Curated Info